Revenue and Profit - Revenue for Q1 2022 was CNY 80,744,800.39, a decrease of 13.44% compared to the same period last year[6] - Net profit attributable to shareholders was CNY 14,292,867.60, an increase of 22.64% year-over-year[6] - Total operating revenue for Q1 2022 was CNY 80,744,800.39, a decrease of 13.4% compared to CNY 93,280,186.12 in Q1 2021[18] - The company reported a net profit of CNY 14,797,683.82 for Q1 2022, compared to a net profit of CNY 13,284,381.40 in Q1 2021[18] - The net profit for Q1 2022 was CNY 14,292,867.60, an increase of 22.3% compared to CNY 11,653,981.88 in Q1 2021[19] - Operating profit for Q1 2022 reached CNY 17,636,111.54, up from CNY 14,153,914.49 in the same period last year, reflecting a growth of 24.3%[19] - The total comprehensive income for Q1 2022 was CNY 14,292,867.60, up from CNY 11,653,981.88 in Q1 2021, reflecting an increase of 22.3%[20] Expenses and Costs - R&D expenses totaled CNY 6,108,108.78, representing 7.56% of revenue, an increase of 1.6 percentage points[7] - Total operating costs for Q1 2022 were CNY 65,947,116.57, down 17.5% from CNY 79,995,804.72 in Q1 2021[18] - Research and development expenses for Q1 2022 were CNY 5,112,082.43, slightly up from CNY 5,011,994.78 in Q1 2021[18] - The company incurred a credit impairment loss of CNY 429,227.24 in Q1 2022, compared to CNY 624,004.03 in Q1 2021, showing a decrease of 31.2%[19] - The company incurred financial expenses of CNY 267,075.46 in Q1 2022, contrasting with a financial income of CNY 252,479.62 in Q1 2021[25] Cash Flow and Liquidity - Operating cash flow for the quarter was CNY 29,565,224.06, up 20.12% from the previous year[7] - Cash flow from operating activities generated a net amount of CNY 29,565,224.06, compared to CNY 24,612,688.81 in Q1 2021, indicating a year-over-year increase of 20.0%[21] - Total cash and cash equivalents at the end of Q1 2022 amounted to CNY 268,158,720.07, significantly higher than CNY 135,737,596.01 at the end of Q1 2021, representing an increase of 97.5%[21] - The company reported cash inflows from investment activities of CNY 201,170,235.62, with a net cash flow from investment activities of CNY 19,110,356.37, compared to a net outflow of CNY 17,353,559.51 in Q1 2021[21] - The company's cash outflow from operating activities totaled CNY 126,590,112.56 in Q1 2022, compared to CNY 110,059,935.17 in Q1 2021, indicating an increase of 15.1%[21] Assets and Liabilities - Total assets at the end of the quarter were CNY 992,618,993.49, an increase of 3.76% from the end of the previous year[7] - Cash and cash equivalents as of March 31, 2022, were CNY 269,428,720.07, an increase from CNY 211,564,862.66 as of December 31, 2021[14] - Inventory as of March 31, 2022, was CNY 113,310,556.00, up from CNY 101,363,001.75 as of December 31, 2021[15] - Total liabilities as of March 31, 2022, were CNY 192,911,128.84, an increase from CNY 171,480,668.76 as of December 31, 2021[16] - The company’s total equity as of March 31, 2022, was CNY 799,707,864.65, compared to CNY 785,137,100.85 as of December 31, 2021[17] Shareholder Information - The company reported a total of 6,406 common shareholders at the end of the reporting period[10] - The largest shareholder, Chengdu Sainuo Investment Co., Ltd., holds 30,000,000 shares, representing 37.5% of total shares[10] Other Financial Metrics - Basic and diluted earnings per share were both CNY 0.18, a decrease of 5.26% compared to the same period last year[7] - The basic and diluted earnings per share for Q1 2022 were both CNY 0.18, slightly down from CNY 0.19 in Q1 2021[20] - The company’s total equity as of the end of Q1 2022 was CNY 509,521,123.28, compared to CNY 509,328,982.40 at the end of Q1 2021[25]
圣诺生物(688117) - 2022 Q1 - 季度财报